EXECUTIVE INSIGHTS
DOMAIN EXPERTS
PLAYERS
PARTICIPANTS
-
OCT 2024
-
EDITION 7
-
TABLES 123
-
REGIONS 12
-
SEGMENTS 8
-
PAGES 193
-
US$ 4950
-
MCP16732
-
JOIN OUR PANEL
EXECUTIVE ENGAGEMENTS BY TIER
-
CXO
-
VICE PRESIDENT
-
DIRECTOR
-
MANAGER
-
MARKETING
HIGHLIGHTS & REPORT INDEX
Global Psoriasis Treatment Market to Reach US$32.4 Billion by 2030
The global market for Psoriasis Treatment estimated at US$21.0 Billion in the year 2023, is expected to reach US$32.4 Billion by 2030, growing at a CAGR of 6.4% over the analysis period 2023-2030. Interleukin Inhibitors, one of the segments analyzed in the report, is expected to record a 6.1% CAGR and reach US$11.8 Billion by the end of the analysis period. Growth in the Corticosteroids segment is estimated at 6.2% CAGR over the analysis period.
The U.S. Market is Estimated at US$5.6 Billion While China is Forecast to Grow at 10.7% CAGR
The Psoriasis Treatment market in the U.S. is estimated at US$5.6 Billion in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$7.8 Billion by the year 2030 trailing a CAGR of 10.7% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.7% and 6.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.3% CAGR.
Global Psoriasis Treatment Market - Key Trends & Drivers Summarized
Why Is the Psoriasis Treatment Market Gaining Prominence in Dermatology?
The psoriasis treatment market is gaining prominence in dermatology due to the increasing prevalence of psoriasis and the growing awareness of the condition among both patients and healthcare providers. Psoriasis is a chronic autoimmune disease characterized by the rapid growth of skin cells, leading to the formation of scaly patches, redness, and inflammation. With rising rates of obesity, metabolic syndrome, and other comorbidities that exacerbate psoriasis, the demand for effective treatment options is on the rise. As healthcare professionals become more attuned to the complexities of psoriasis and its impact on patients’ quality of life, there is a growing emphasis on developing and providing comprehensive treatment strategies that encompass both physical and psychological aspects.
One of the primary factors driving the growth of the psoriasis treatment market is the increasing availability of innovative therapies, including biologics, systemic medications, and topical treatments. Recent advancements in medical research have led to the development of targeted therapies that address specific pathways involved in the pathogenesis of psoriasis. Biologics, which are derived from living cells, have revolutionized the treatment landscape by offering effective and long-lasting solutions for moderate to severe psoriasis. These new therapies not only improve symptoms but also significantly enhance the overall quality of life for patients, driving the adoption of psoriasis treatments in clinical practice.
How Are Technological Advancements and Innovations Shaping the Psoriasis Treatment Market?
Technological advancements and innovations are significantly shaping the psoriasis treatment market by improving treatment options, enhancing patient monitoring, and personalizing care. One notable development is the evolution of biologic therapies, which target specific components of the immune system to reduce inflammation and skin cell proliferation. This class of medications has expanded treatment options for patients with moderate to severe psoriasis, providing more effective and tailored solutions. The introduction of oral biologics and biosimilars is also expected to increase access to treatment and reduce costs, further driving market growth.
Additionally, advancements in telemedicine and digital health technologies are transforming the way psoriasis is managed. Remote consultations and digital monitoring tools enable healthcare providers to assess patients’ conditions more efficiently, ensuring timely adjustments to treatment plans. Mobile applications and wearable devices that track symptoms and treatment adherence are becoming increasingly popular, empowering patients to take control of their condition. This trend towards personalized and remote care is enhancing the overall treatment experience for psoriasis patients and contributing to the growth of the market.
Moreover, ongoing research and development efforts in the field of psoriasis are leading to the discovery of new therapeutic targets and treatment modalities. Clinical trials are continuously exploring novel compounds and combination therapies that offer improved efficacy and safety profiles. The expansion of treatment options, including emerging therapies and novel drug formulations, is expected to enhance patient outcomes and satisfaction. This focus on innovation and research is a critical driver of growth in the psoriasis treatment market.
Furthermore, the increasing emphasis on holistic approaches to psoriasis management is shaping treatment strategies. Healthcare providers are recognizing the importance of addressing not only the physical symptoms but also the psychological and emotional impact of psoriasis. Integrating mental health support, lifestyle modifications, and complementary therapies into treatment plans is becoming more common. This comprehensive approach is driving the demand for multifaceted treatment solutions that can effectively address the complexities of psoriasis.
What Role Do Market Dynamics and Regulatory Trends Play in Shaping the Adoption of Psoriasis Treatments?
Market dynamics and regulatory trends play a crucial role in shaping the adoption of psoriasis treatments as industries respond to changing demands for effective therapies and compliance with regulations. The increasing prevalence of psoriasis is a key driver of the market, with millions of individuals affected worldwide. As healthcare providers become more aware of the need for effective treatment options, the adoption of advanced therapies is becoming essential. The ability to provide comprehensive treatment solutions that address the diverse needs of psoriasis patients is enhancing the market`s appeal and driving adoption.
Regulatory pressures surrounding drug approvals and safety standards are also influencing the adoption of psoriasis treatments. Regulatory agencies, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), have established stringent guidelines for the approval and monitoring of psoriasis therapies. Compliance with these regulations is essential for manufacturers seeking to bring new products to market. The focus on rigorous testing and safety profiles enhances consumer confidence in available treatments, driving their adoption among healthcare providers and patients.
The competitive landscape within the dermatology and biopharmaceutical industries is another significant factor shaping the adoption of psoriasis treatments. Numerous manufacturers are entering the market, offering a wide range of treatment options tailored to specific patient needs. This competition is driving innovation and improvements in product quality, allowing manufacturers to meet the diverse requirements of different sectors. The focus on product differentiation, including the development of novel biologics and combination therapies, is enhancing the market presence of psoriasis treatments and contributing to their widespread adoption.
Consumer preferences for effective, reliable, and safe psoriasis treatments are also influencing adoption. As patients become more informed about their treatment options, there is a growing demand for therapies that provide fast and long-lasting results. Manufacturers are responding by developing treatments that offer improved efficacy and safety profiles, including options that minimize side effects. The ability to provide high-quality psoriasis treatments that meet the evolving needs of consumers is essential for manufacturers looking to gain a competitive edge in the market.
What Factors Are Driving the Growth of the Global Psoriasis Treatment Market?
The growth in the global psoriasis treatment market is driven by several factors, including the rising prevalence of psoriasis, advancements in therapeutic options, and ongoing research and development efforts. One of the primary growth drivers is the increasing awareness and diagnosis of psoriasis among healthcare professionals and patients. Improved understanding of the condition and its implications has led to more individuals seeking treatment, creating a larger patient base that requires effective therapeutic solutions.
The advancement of innovative therapies, particularly biologics and targeted treatments, is another key factor contributing to market growth. Biologics have transformed the treatment landscape for moderate to severe psoriasis, offering more effective and personalized solutions. The emergence of oral biologics and biosimilars is expected to further increase access to treatment and reduce costs, promoting the adoption of these therapies. The continuous development of new and improved treatment options is expected to fuel market growth as more effective therapies become available.
Ongoing research and development efforts in the field of dermatology are also supporting the growth of the psoriasis treatment market. Researchers are exploring new compounds and treatment modalities that target specific pathways involved in the pathogenesis of psoriasis. This focus on innovation is paving the way for the development of targeted therapies that can provide better outcomes for patients. The investment in R&D by biopharmaceutical companies is expected to lead to the introduction of novel treatment options, driving market expansion.
Moreover, the increasing focus on patient-centered care and holistic approaches to psoriasis management is creating new opportunities for the market. Healthcare providers are recognizing the importance of addressing the psychological and emotional impact of psoriasis, leading to integrated treatment approaches that include mental health support and lifestyle modifications. This trend towards comprehensive care is driving demand for multifaceted treatment solutions that can effectively address the complexities of psoriasis.
Additionally, the impact of the COVID-19 pandemic has heightened awareness of chronic health conditions, including psoriasis. As healthcare systems adapt to new challenges, there is a renewed focus on ensuring that patients receive the necessary care and support for their conditions. This emphasis on continuity of care is expected to drive the demand for psoriasis treatments, reinforcing the market`s growth trajectory.
As these factors converge, the global psoriasis treatment market is poised for robust growth, driven by advancements in therapeutic options, expanding patient awareness, and the increasing emphasis on improving health outcomes across various healthcare sectors.
SCOPE OF STUDY
The report analyzes the Psoriasis Treatment market by the following Segments, and Geographic Regions/Countries:
Segments:
Drug Class (Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues, Other Drug Classes); Route of Administration (Parenteral, Oral, Topical).
Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World..
SELECT PLAYERS
AbbVie, Inc.; Amgen, Inc.; Eli Lilly and Company; Johnson & Johnson; Merck & Co., Inc.; Novartis International AG; Pfizer, Inc.
TABLE OF CONTENTS
I. METHODOLOGY |
II. EXECUTIVE SUMMARY |
1. MARKET OVERVIEW |
Influencer Market Insights |
World Market Trajectories |
Psoriasis Treatment – Global Key Competitors Percentage Market Share in 2024 (E) |
Competitive Market Presence - Strong/Active/Niche/Trivial for 44 Players Worldwide in 2024 (E) |
2. FOCUS ON SELECT PLAYERS |
3. MARKET TRENDS & DRIVERS |
Rising Prevalence of Psoriasis and Psoriatic Arthritis Propels Growth in Psoriasis Treatment Market |
Increasing Adoption of Biologic Therapies in Moderate to Severe Psoriasis Expands Addressable Market |
Innovations in Topical Therapies Strengthen Business Case for Market Growth |
Increasing Use of Psoriasis Treatment in Dermatology and Specialty Clinics Expands Market Scope |
Technological Advancements in Oral and Injectable Biologics Propel Market Growth |
Case Overview: Growth in Adoption of Psoriasis Treatments in At-Home and Over-The-Counter Products Expands Market Reach |
Case Overview: Growth in Use of Psoriasis Treatment in Scalp and Nail Psoriasis Expands Market Reach |
Technological Advancements in Light and Laser-Based Psoriasis Therapies Propel Market Growth |
4. GLOBAL MARKET PERSPECTIVE |
World Psoriasis Treatment Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030 |
World Recent Past, Current & Future Analysis for Psoriasis Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR |
World Historic Review for Psoriasis Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
World 16-Year Perspective for Psoriasis Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030 |
World Recent Past, Current & Future Analysis for Interleukin Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR |
World Historic Review for Interleukin Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
World 16-Year Perspective for Interleukin Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030 |
World Recent Past, Current & Future Analysis for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR |
World Historic Review for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
World 16-Year Perspective for Corticosteroids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030 |
World Recent Past, Current & Future Analysis for Tumor Necrosis Factor (TNF) Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR |
World Historic Review for Tumor Necrosis Factor (TNF) Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
World 16-Year Perspective for Tumor Necrosis Factor (TNF) Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030 |
World Recent Past, Current & Future Analysis for Vitamin D Analogues by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR |
World Historic Review for Vitamin D Analogues by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
World 16-Year Perspective for Vitamin D Analogues by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030 |
World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR |
World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
World 16-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030 |
World Recent Past, Current & Future Analysis for Parenteral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR |
World Historic Review for Parenteral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
World 16-Year Perspective for Parenteral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030 |
World Recent Past, Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR |
World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
World 16-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030 |
World Recent Past, Current & Future Analysis for Topical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR |
World Historic Review for Topical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
World 16-Year Perspective for Topical by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030 |
III. MARKET ANALYSIS |
UNITED STATES |
Psoriasis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E) |
USA Recent Past, Current & Future Analysis for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
USA Historic Review for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
USA 16-Year Perspective for Psoriasis Treatment by Drug Class - Percentage Breakdown of Value Sales for Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes for the Years 2014, 2024 & 2030 |
USA Recent Past, Current & Future Analysis for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
USA Historic Review for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
USA 16-Year Perspective for Psoriasis Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Topical for the Years 2014, 2024 & 2030 |
CANADA |
Canada Recent Past, Current & Future Analysis for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Canada Historic Review for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Canada 16-Year Perspective for Psoriasis Treatment by Drug Class - Percentage Breakdown of Value Sales for Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes for the Years 2014, 2024 & 2030 |
Canada Recent Past, Current & Future Analysis for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Canada Historic Review for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Canada 16-Year Perspective for Psoriasis Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Topical for the Years 2014, 2024 & 2030 |
JAPAN |
Psoriasis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E) |
Japan Recent Past, Current & Future Analysis for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Japan Historic Review for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Japan 16-Year Perspective for Psoriasis Treatment by Drug Class - Percentage Breakdown of Value Sales for Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes for the Years 2014, 2024 & 2030 |
Japan Recent Past, Current & Future Analysis for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Japan Historic Review for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Japan 16-Year Perspective for Psoriasis Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Topical for the Years 2014, 2024 & 2030 |
CHINA |
Psoriasis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E) |
China Recent Past, Current & Future Analysis for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
China Historic Review for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
China 16-Year Perspective for Psoriasis Treatment by Drug Class - Percentage Breakdown of Value Sales for Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes for the Years 2014, 2024 & 2030 |
China Recent Past, Current & Future Analysis for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
China Historic Review for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
China 16-Year Perspective for Psoriasis Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Topical for the Years 2014, 2024 & 2030 |
EUROPE |
Psoriasis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E) |
Europe Recent Past, Current & Future Analysis for Psoriasis Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR |
Europe Historic Review for Psoriasis Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Europe 16-Year Perspective for Psoriasis Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030 |
Europe Recent Past, Current & Future Analysis for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Europe Historic Review for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Europe 16-Year Perspective for Psoriasis Treatment by Drug Class - Percentage Breakdown of Value Sales for Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes for the Years 2014, 2024 & 2030 |
Europe Recent Past, Current & Future Analysis for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Europe Historic Review for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Europe 16-Year Perspective for Psoriasis Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Topical for the Years 2014, 2024 & 2030 |
FRANCE |
Psoriasis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E) |
France Recent Past, Current & Future Analysis for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
France Historic Review for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
France 16-Year Perspective for Psoriasis Treatment by Drug Class - Percentage Breakdown of Value Sales for Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes for the Years 2014, 2024 & 2030 |
France Recent Past, Current & Future Analysis for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
France Historic Review for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
France 16-Year Perspective for Psoriasis Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Topical for the Years 2014, 2024 & 2030 |
GERMANY |
Psoriasis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E) |
Germany Recent Past, Current & Future Analysis for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Germany Historic Review for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Germany 16-Year Perspective for Psoriasis Treatment by Drug Class - Percentage Breakdown of Value Sales for Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes for the Years 2014, 2024 & 2030 |
Germany Recent Past, Current & Future Analysis for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Germany Historic Review for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Germany 16-Year Perspective for Psoriasis Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Topical for the Years 2014, 2024 & 2030 |
ITALY |
Italy Recent Past, Current & Future Analysis for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Italy Historic Review for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Italy 16-Year Perspective for Psoriasis Treatment by Drug Class - Percentage Breakdown of Value Sales for Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes for the Years 2014, 2024 & 2030 |
Italy Recent Past, Current & Future Analysis for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Italy Historic Review for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Italy 16-Year Perspective for Psoriasis Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Topical for the Years 2014, 2024 & 2030 |
UNITED KINGDOM |
Psoriasis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E) |
UK Recent Past, Current & Future Analysis for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
UK Historic Review for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
UK 16-Year Perspective for Psoriasis Treatment by Drug Class - Percentage Breakdown of Value Sales for Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes for the Years 2014, 2024 & 2030 |
UK Recent Past, Current & Future Analysis for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
UK Historic Review for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
UK 16-Year Perspective for Psoriasis Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Topical for the Years 2014, 2024 & 2030 |
SPAIN |
Spain Recent Past, Current & Future Analysis for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Spain Historic Review for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Spain 16-Year Perspective for Psoriasis Treatment by Drug Class - Percentage Breakdown of Value Sales for Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes for the Years 2014, 2024 & 2030 |
Spain Recent Past, Current & Future Analysis for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Spain Historic Review for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Spain 16-Year Perspective for Psoriasis Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Topical for the Years 2014, 2024 & 2030 |
RUSSIA |
Russia Recent Past, Current & Future Analysis for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Russia Historic Review for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Russia 16-Year Perspective for Psoriasis Treatment by Drug Class - Percentage Breakdown of Value Sales for Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes for the Years 2014, 2024 & 2030 |
Russia Recent Past, Current & Future Analysis for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Russia Historic Review for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Russia 16-Year Perspective for Psoriasis Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Topical for the Years 2014, 2024 & 2030 |
REST OF EUROPE |
Rest of Europe Recent Past, Current & Future Analysis for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Rest of Europe Historic Review for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Rest of Europe 16-Year Perspective for Psoriasis Treatment by Drug Class - Percentage Breakdown of Value Sales for Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes for the Years 2014, 2024 & 2030 |
Rest of Europe Recent Past, Current & Future Analysis for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Rest of Europe Historic Review for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Rest of Europe 16-Year Perspective for Psoriasis Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Topical for the Years 2014, 2024 & 2030 |
ASIA-PACIFIC |
Psoriasis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E) |
Asia-Pacific Recent Past, Current & Future Analysis for Psoriasis Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR |
Asia-Pacific Historic Review for Psoriasis Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Asia-Pacific 16-Year Perspective for Psoriasis Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030 |
Asia-Pacific Recent Past, Current & Future Analysis for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Asia-Pacific Historic Review for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Asia-Pacific 16-Year Perspective for Psoriasis Treatment by Drug Class - Percentage Breakdown of Value Sales for Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes for the Years 2014, 2024 & 2030 |
Asia-Pacific Recent Past, Current & Future Analysis for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Asia-Pacific Historic Review for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Asia-Pacific 16-Year Perspective for Psoriasis Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Topical for the Years 2014, 2024 & 2030 |
AUSTRALIA |
Psoriasis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E) |
Australia Recent Past, Current & Future Analysis for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Australia Historic Review for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Australia 16-Year Perspective for Psoriasis Treatment by Drug Class - Percentage Breakdown of Value Sales for Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes for the Years 2014, 2024 & 2030 |
Australia Recent Past, Current & Future Analysis for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Australia Historic Review for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Australia 16-Year Perspective for Psoriasis Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Topical for the Years 2014, 2024 & 2030 |
INDIA |
Psoriasis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E) |
India Recent Past, Current & Future Analysis for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
India Historic Review for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
India 16-Year Perspective for Psoriasis Treatment by Drug Class - Percentage Breakdown of Value Sales for Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes for the Years 2014, 2024 & 2030 |
India Recent Past, Current & Future Analysis for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
India Historic Review for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
India 16-Year Perspective for Psoriasis Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Topical for the Years 2014, 2024 & 2030 |
SOUTH KOREA |
South Korea Recent Past, Current & Future Analysis for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
South Korea Historic Review for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
South Korea 16-Year Perspective for Psoriasis Treatment by Drug Class - Percentage Breakdown of Value Sales for Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes for the Years 2014, 2024 & 2030 |
South Korea Recent Past, Current & Future Analysis for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
South Korea Historic Review for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
South Korea 16-Year Perspective for Psoriasis Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Topical for the Years 2014, 2024 & 2030 |
REST OF ASIA-PACIFIC |
Rest of Asia-Pacific Recent Past, Current & Future Analysis for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Rest of Asia-Pacific Historic Review for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Rest of Asia-Pacific 16-Year Perspective for Psoriasis Treatment by Drug Class - Percentage Breakdown of Value Sales for Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes for the Years 2014, 2024 & 2030 |
Rest of Asia-Pacific Recent Past, Current & Future Analysis for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Rest of Asia-Pacific Historic Review for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Rest of Asia-Pacific 16-Year Perspective for Psoriasis Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Topical for the Years 2014, 2024 & 2030 |
LATIN AMERICA |
Psoriasis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E) |
Latin America Recent Past, Current & Future Analysis for Psoriasis Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR |
Latin America Historic Review for Psoriasis Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Latin America 16-Year Perspective for Psoriasis Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030 |
Latin America Recent Past, Current & Future Analysis for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Latin America Historic Review for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Latin America 16-Year Perspective for Psoriasis Treatment by Drug Class - Percentage Breakdown of Value Sales for Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes for the Years 2014, 2024 & 2030 |
Latin America Recent Past, Current & Future Analysis for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Latin America Historic Review for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Latin America 16-Year Perspective for Psoriasis Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Topical for the Years 2014, 2024 & 2030 |
ARGENTINA |
Argentina Recent Past, Current & Future Analysis for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Argentina Historic Review for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Argentina 16-Year Perspective for Psoriasis Treatment by Drug Class - Percentage Breakdown of Value Sales for Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes for the Years 2014, 2024 & 2030 |
Argentina Recent Past, Current & Future Analysis for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Argentina Historic Review for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Argentina 16-Year Perspective for Psoriasis Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Topical for the Years 2014, 2024 & 2030 |
BRAZIL |
Brazil Recent Past, Current & Future Analysis for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Brazil Historic Review for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Brazil 16-Year Perspective for Psoriasis Treatment by Drug Class - Percentage Breakdown of Value Sales for Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes for the Years 2014, 2024 & 2030 |
Brazil Recent Past, Current & Future Analysis for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Brazil Historic Review for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Brazil 16-Year Perspective for Psoriasis Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Topical for the Years 2014, 2024 & 2030 |
MEXICO |
Mexico Recent Past, Current & Future Analysis for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Mexico Historic Review for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Mexico 16-Year Perspective for Psoriasis Treatment by Drug Class - Percentage Breakdown of Value Sales for Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes for the Years 2014, 2024 & 2030 |
Mexico Recent Past, Current & Future Analysis for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Mexico Historic Review for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Mexico 16-Year Perspective for Psoriasis Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Topical for the Years 2014, 2024 & 2030 |
REST OF LATIN AMERICA |
Rest of Latin America Recent Past, Current & Future Analysis for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Rest of Latin America Historic Review for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Rest of Latin America 16-Year Perspective for Psoriasis Treatment by Drug Class - Percentage Breakdown of Value Sales for Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes for the Years 2014, 2024 & 2030 |
Rest of Latin America Recent Past, Current & Future Analysis for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Rest of Latin America Historic Review for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Rest of Latin America 16-Year Perspective for Psoriasis Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Topical for the Years 2014, 2024 & 2030 |
MIDDLE EAST |
Psoriasis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E) |
Middle East Recent Past, Current & Future Analysis for Psoriasis Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR |
Middle East Historic Review for Psoriasis Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Middle East 16-Year Perspective for Psoriasis Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030 |
Middle East Recent Past, Current & Future Analysis for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Middle East Historic Review for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Middle East 16-Year Perspective for Psoriasis Treatment by Drug Class - Percentage Breakdown of Value Sales for Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes for the Years 2014, 2024 & 2030 |
Middle East Recent Past, Current & Future Analysis for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Middle East Historic Review for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Middle East 16-Year Perspective for Psoriasis Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Topical for the Years 2014, 2024 & 2030 |
IRAN |
Iran Recent Past, Current & Future Analysis for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Iran Historic Review for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Iran 16-Year Perspective for Psoriasis Treatment by Drug Class - Percentage Breakdown of Value Sales for Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes for the Years 2014, 2024 & 2030 |
Iran Recent Past, Current & Future Analysis for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Iran Historic Review for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Iran 16-Year Perspective for Psoriasis Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Topical for the Years 2014, 2024 & 2030 |
ISRAEL |
Israel Recent Past, Current & Future Analysis for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Israel Historic Review for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Israel 16-Year Perspective for Psoriasis Treatment by Drug Class - Percentage Breakdown of Value Sales for Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes for the Years 2014, 2024 & 2030 |
Israel Recent Past, Current & Future Analysis for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Israel Historic Review for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Israel 16-Year Perspective for Psoriasis Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Topical for the Years 2014, 2024 & 2030 |
SAUDI ARABIA |
Saudi Arabia Recent Past, Current & Future Analysis for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Saudi Arabia Historic Review for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Saudi Arabia 16-Year Perspective for Psoriasis Treatment by Drug Class - Percentage Breakdown of Value Sales for Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes for the Years 2014, 2024 & 2030 |
Saudi Arabia Recent Past, Current & Future Analysis for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Saudi Arabia Historic Review for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Saudi Arabia 16-Year Perspective for Psoriasis Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Topical for the Years 2014, 2024 & 2030 |
UNITED ARAB EMIRATES |
UAE Recent Past, Current & Future Analysis for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
UAE Historic Review for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
UAE 16-Year Perspective for Psoriasis Treatment by Drug Class - Percentage Breakdown of Value Sales for Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes for the Years 2014, 2024 & 2030 |
UAE Recent Past, Current & Future Analysis for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
UAE Historic Review for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
UAE 16-Year Perspective for Psoriasis Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Topical for the Years 2014, 2024 & 2030 |
REST OF MIDDLE EAST |
Rest of Middle East Recent Past, Current & Future Analysis for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Rest of Middle East Historic Review for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Rest of Middle East 16-Year Perspective for Psoriasis Treatment by Drug Class - Percentage Breakdown of Value Sales for Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes for the Years 2014, 2024 & 2030 |
Rest of Middle East Recent Past, Current & Future Analysis for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Rest of Middle East Historic Review for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Rest of Middle East 16-Year Perspective for Psoriasis Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Topical for the Years 2014, 2024 & 2030 |
AFRICA |
Psoriasis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E) |
Africa Recent Past, Current & Future Analysis for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Africa Historic Review for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Africa 16-Year Perspective for Psoriasis Treatment by Drug Class - Percentage Breakdown of Value Sales for Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes for the Years 2014, 2024 & 2030 |
Africa Recent Past, Current & Future Analysis for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Africa Historic Review for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Africa 16-Year Perspective for Psoriasis Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Topical for the Years 2014, 2024 & 2030 |
IV. COMPETITION |
PREVIEW REPORT
Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.
What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com